PTC Therapeutics, Inc. 154.5% Potential Upside Now Implied by Wedbush
Mar 02 2016
PTC Therapeutics, Inc is under investigation over possible securities laws violations. 6 analysts have added the shares in their list of strong buys. Parametrica Management bought a new position in shares of PTC Therapeutics during the fourth quarter valued at about $519,000.
Bb Biotech Ag holds 1.1% of its portfolio in PTC Therapeutics, Inc. for 1.30 million shares. A number of equities research analysts have recently issued reports on PTCT shares. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.25) by $0.25.
According to a research note published on 24/02/2016, analysts at Citigroup have lowered their rating on the company stock from Buy to Neutral. The 52-week high of PTC Therapeutics (NASDAQ:PTCT) is $78.72 and the 52-week low is $7.83. The firm's market cap is $227.57 million. Investors should note that the Company has disclosed insider buying and selling activities to the Securities Exchange, Southwell David P, director of Ptc Therapeutics, Inc., unloaded 23,604 shares at an average price of $47.86 on July 6, 2015. (NASDAQ:PTCT) to release earnings on February, 29 after the close.
Presently the company Insiders own 10.1% of PTC Therapeutics shares according to the proxy statements. ProShare Advisors LLC now owns 32,490 shares of the biopharmaceutical company's stock worth $1,053,000 after buying an additional 3,122 shares during the period. Putnam Investments LLC increased its stake in PTC Therapeutics by 48.1% in the fourth quarter.
Rhumbline Advisers now owns 33,247 shares of the biopharmaceutical company's stock valued at $1,077,000 after buying an additional 2,485 shares during the last quarter. Alliancebernstein L.P. now owns 1,285,485 shares of the biopharmaceutical company's stock valued at $41,650,000 after buying an additional 254,361 shares in the last quarter.
United Services Automobile Association increased its stake in PTC Therapeutics by 15.9% in the fourth quarter. The analysts also projected the company's long-term growth at -9.51 percent for the upcoming five years. Oppenheimer restated an outperform rating and issued a $135.00 price objective on shares of PTC Therapeutics in a research note on Wednesday, November 11th.
PTC Therapeutics, Inc. with TICKER NASDAQ:PTCT has had its stock rating noted as "Reiterated" with the recommendation being set at "OUTPERFORM" yesterday by research analysts at Wedbush. Finally, Credit Suisse began coverage on PTC Therapeutics in a research note on Tuesday, January 19th. The firm presently has a "sector perform" rating on the biopharmaceutical company's stock. The mean price target is calculated keeping in view the consensus of 10 brokerage firms. The Company's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases.
Total revenues for the fourth quarter of 2015 were $12.7 million compared to $12.7 million in the same period of 2014. That is compared with the $-0.84 in earnings per share it reported during the same period previous year.